Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
53°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
79.00
-0.45 (-0.57%)
Official Closing Price
Updated: 4:15 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
December 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Commits to Electrifying Its Fleet
November 16, 2021
SOURCE: Gilead Sciences
Via
3BL Media
HIV Advisory Council in Australia Taps Diverse Community Perspectives
December 09, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
December 08, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit...
Via
FinancialNewsMedia
Gilead Sciences Ranked No. 6 overall, and No. 2 in Health Care & Life Sciences Industry, in Newsweek's List of Most Responsible American Companies
December 07, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gildead Sciences Is Proud to Be a Presenting Partner of National AIDS Memorial's World AIDS Day: December 1, 2021
December 01, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Added to the Dow Jones Sustainability World Index
November 30, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Stocks
Exposures
US Equities
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
November 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
November 23, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
The Importance of Self Advocacy in Breast Cancer: Janelle's Story
November 23, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Product Recall
Exposures
Legal
Product Safety
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
November 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
India's Efforts to Help End Hepatitis C Starts With Prison Population
November 18, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Death
Exposures
COVID-19
Death
Kerri Fitzpatrick Puts Patients Front and Center
November 12, 2021
SOURCE: Gilead Sciences
Via
3BL Media
BA Insight for Amazon OpenSearch Service and BA Insight for Amazon Kendra Available Immediately in AWS Marketplace
November 12, 2021
BOSTON - Nov. 12, 2021 - PRLog -- BA Insight has today announced availability of two Amazon Web Services Marketplace offerings: BA Insight for Amazon OpenSearch Service and BA Insight for Amazon...
Via
PRLog
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
November 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
November 09, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Thumbi Ndung'u on Thinking Beyond Lifelong Treatment in HIV
November 09, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
November 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Healthcare Nanotechnology (Nanomedicine) Market Next Big Thing : Gilead Sciences, Pfizer, 3M
November 10, 2021
The latest independent research document on Worldwide Healthcare Nanotechnology (Nanomedicine) examine investment in Market.
Via
SBWire
'Inside the Innovation:' Oncology Leaders Discuss Life at Gilead
November 02, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
October 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
October 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Four Questions With Sade Clacken Joseph: Using Film As a Change Agent
October 26, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Religion
Exposures
Religion
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
October 26, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Global Parkinsons Disease Drugs Market Market Development Overview 2021:Johnson & Johnson, Gilead Sciences, Pacira
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Parkinsons Disease Drugs market in its latest report. All of the market forecasts presented in the report are...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.